REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) is a clinical-stage biopharmaceutical company that entered the public markets through a SPAC transaction, operating within the healthcare and life sciences sector. The company filed an 8-K with the Securities and Exchange Commission on July 24, 2020, under accession number 0001104659-20-086490, disclosing material corporate developments in accordance with SEC reporting obligations. Reviva is focused on developing drug candidates targeting central nervous system and metabolic conditions, and has maintained an active public reporting record since completing its SPAC-related listing. For comprehensive filing history, sponsor details, deal timelines, and analytical data on RVPH and the broader SPAC universe, sign up for full access at SpacDesk.